Cited by 110Fibroblast Growth Factor ResearchLiver Disease Diagnosis and TreatmentDiabetes Treatment and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Open access

Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., Bajaj, M.·2011·Diabetologia

DOI 10.1007/s00125-011-2317-zPMC PMC3658171

Open this paper in CoChat — free account Open PDF

Abstract

Aims/hypothesis Systemic fibroblast growth factor (FGF)21 levels and hepatic FGF21 production are increased in non-alcoholic fatty liver disease patients, suggesting FGF21 resistance. We examined the effects of exenatide on FGF21 in patients with type 2 diabetes and in a diet-induced mouse model of obesity (DIO).Methods Type 2 diabetes mellitus patients (n = 24) on diet and/or metformin were randomised (using a table of random numbers) to receive additional treatment consisting of pioglitazone 45 mg/day or combined therapy with pioglitazone (45 mg/day) and exenatide (10 μg twice daily) for 12 months in an open label parallel study at the Baylor Clinic.Results Twenty-one patients completed the entire study and were included in the analysis. Pioglitazone treatment (n = 10) reduced hepatic fat as assessed by magnetic resonance spectroscopy, despite a significant increase in body weight (Δ = 3.7 kg); plasma FGF21 levels did not change (1.9 ± 0.6 to 2.2 ± 0.6 ng/ml [mean ± SEM]). However, combined pioglitazone and exenatide therapy (n = 11) was associated with a significant reduction of FGF21 levels (2.3 ± 0.5 to 1.1 ± 0.3 ng/ml) and a greater decrease in hepatic fat. Besides weight gain observed in the pioglitazone-treated patients, lower extremity oedema was observed as a side effect in two of the ten patients. Three patients who received pioglitazone and exenatide combination therapy complained of significant nausea that was self-limiting and did not require them to leave the study. In DIO mice, exendin-4 for 4 weeks significantly reduced hepatic triacylglycerol content, decreased hepatic FGF21 protein and mRNA, and enhanced phosphorylation of hepatic AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase, although no significant difference in weight and body fat was observed. Hepatic FGF21 correlated inversely with hepatic AMPK phosphorylation Conclusions/interpretation In type 2 diabetes mellitus, combined pioglitazone and exenatide therapy is associated with a reduction in plasma FGF21 levels, as well as a greater decrease in hepatic fat than that achieved with pioglitazone therapy. In DIO mice, exendin-4 treatment reduces hepatic triacylglycerol and FGF21 protein, and enhances hepatic AMPK phosphorylation, suggesting an improvement of hepatic FGF21 resistance.Trial registration number ClinicalTrials.gov NCT 01432405.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-011-2317-z

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
FGF-21 as a novel metabolic regulator
Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23606 · Cited by 2,125
Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice
Xu, J., Lloyd, D. J., Hale, C., Stanislaus, S., Chen, M., Sivits, G., Vonderfecht, S., Hecht, R., Li, Y.-S., Lindberg, R. A., et al. (2009) · Diabetes · doi:10.2337/db08-0392 · Cited by 1,151
Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State
Fisher, F. M., Chui, P. C., Antonellis, P. J., Bina, H. A., Kharitonenkov, A., Flier, J. S., & Maratos-Flier, E. (2010) · Diabetes · doi:10.2337/db10-0193 · Cited by 830
The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes
Mayerson, A. B., Hundal, R. S., Dufour, S., Lebon, V., Befroy, D., Cline, G. W., Enocksson, S., Inzucchi, S. E., Shulman, G. I., & Petersen, K. F. (2002) · Diabetes · doi:10.2337/diabetes.51.3.797 · Cited by 647
Increased Fibroblast Growth Factor 21 in Obesity and Nonalcoholic Fatty Liver Disease
Dushay, J., Chui, P. C., Gopalakrishnan, G. S., Varela–Rey, M., Crawley, M., Fisher, F. M., Badman, M. K., Martinez–Chantar, M. L., & Maratos–Flier, E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.04.054 · Cited by 607
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK–SIRT1–PGC-1α pathway
Chau, M. D. L., Gao, J., Yang, Q., Wu, Z., & Gromada, J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006962107 · Cited by 557
Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2
Gutzwiller, J., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 518
Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance
Chavez, A. O., Molina-Carrion, M., Abdul-Ghani, M. A., Folli, F., DeFronzo, R. A., & Tripathy, D. (2009) · Diabetes Care · doi:10.2337/dc09-0684 · Cited by 390

Show all 21 references

Sorted by citations

Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Gastaldelli, A., & Cusi, K. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.07.002 · Cited by 455
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice
Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease
Torres, D. M., Williams, C. D., & Harrison, S. A. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.03.011 · Cited by 275
Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
Dutour, A., Abdesselam, I., Ancel, P., Kober, F., Mrad, G., Darmon, P., Ronsin, O., Pradel, V., Lesavre, N., Martin, J. C., et al. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12680 · Cited by 262
Therapeutic Landscape for NAFLD in 2020
Neuschwander‐Tetri, B. A. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.01.051 · Cited by 184
Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease
Nobili, V., Alisi, A., Newton, K. P., & Schwimmer, J. B. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.03.009 · Cited by 174
Going Back to the Biology of FGF21: New Insights
Lewis, J. E., Ebling, F. J. P., Samms, R. J., & Tsintzas, K. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.05.007 · Cited by 170
FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance
Szczepańska, E., & Gietka‐Czernel, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1778-4159 · Cited by 155
The effectiveness of liraglutide in nonalcoholic fatty liver disease patients with type 2 diabetes mellitus compared to sitagliptin and pioglitazone
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., Tagawa, K., Omata, M., & Koike, K. (2012) · The Scientific World Journal · doi:10.1100/2012/496453 · Cited by 139
Non-alcoholic fatty liver disease and thyroid dysfunction: A systematic review
Eshraghian, A. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i25.8102 · Cited by 145
The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy
Liu, J., Xu, Y., Hu, Y., & Wang, G. (2014) · Metabolism · doi:10.1016/j.metabol.2014.11.009 · Cited by 139
Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
Han, M. A. T., Altayar, O., Hamdeh, S., Takyar, V. K., Rotman, Y., Etzion, O., Lefebvre, E. A., Safadi, R., Ratziu, V., Prokop, L. J., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.06.011 · Cited by 135
miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression
Hanin, G., Yayon, N., Tzur, Y., Haviv, R., Bennett, E. R., Udi, S., Krishnamoorthy, Y. R., Kotsiliti, E., Zangen, R., Efron, B., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312869 · Cited by 132
Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?
Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.073 · Cited by 123
MECHANISMS IN ENDOCRINOLOGY: Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21
Iglesias, P., Selgas, R., Romero, S., & Díez, J. J. (2012) · European Journal of Endocrinology · doi:10.1530/eje-12-0357 · Cited by 113
Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial
Qin, Y., Zhou, Y. G., Chen, S., Zhao, X.-L., Ran, L., Zeng, X.-L., Wu, Y., Chen, J., Kang, C., Shu, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133496 · Cited by 104
Endurance Exercise Reduces Hepatic Fat Content and Serum Fibroblast Growth Factor 21 Levels in Elderly Men
Taniguchi, H., Tanisawa, K., Sun, X., Kubo, T., & Higuchi, M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3308 · Cited by 104
Impaired mitochondrial fatty acid oxidation and insulin resistance in aging: novel protective role of glutathione
Nguyen, D. J. M., Samson, S. L., Reddy, V. T., GONZALEZ, E. V., & Sekhar, R. V. (2013) · Aging Cell · doi:10.1111/acel.12073 · Cited by 99
Self-citation
Endocrine causes of nonalcoholic fatty liver disease
Marino, L. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 93
Incretin‐based therapies for the treatment of non‐alcoholic fatty liver disease: A systematic review and meta‐analysis
Carbone, L. J., Angus, P., & Yeomans, N. D. (2015) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13026 · Cited by 91
Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus
So, W. Y., & Leung, P. S. (2016) · Medicinal Research Reviews · doi:10.1002/med.21390 · Cited by 85
Circulating FGF21 Levels in Human Health and Metabolic Disease
Keuper, M., Häring, H., & Staiger, H. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0879-2968 · Cited by 83
GLP-1 receptor agonists in NAFLD
Petit, J.-M., & Vergès, B. L. (2017) · Diabetes & Metabolism · doi:10.1016/s1262-3636(17)30070-8 · Cited by 72
The Nuanced Metabolic Functions of Endogenous FGF21 Depend on the Nature of the Stimulus, Tissue Source, and Experimental Model
Spann, R. A., Morrison, C. D., & den Hartigh, L. J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.802541 · Cited by 76
Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
Bifari, F., Manfrini, R., Dei, M., Berra, C., Siano, M., Zuin, M. G., Paroni, R. C., & Folli, F. B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 71
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Current status and future perspectives of FGF21 analogues in clinical trials
Chui, Z. S. W., Shen, Q., & Xu, A. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.02.001 · Cited by 70
FGF21 as a mediator of adaptive responses to stress and metabolic benefits of anti-diabetic drugs
Kim, K. H., & Lee, M. (2015) · Journal of Endocrinology · doi:10.1530/joe-15-0160 · Cited by 66
Exendin-4 attenuates cardiac hypertrophy via AMPK/mTOR signaling pathway activation
Zhou, Y., He, X., Chen, Y., Huang, Y., Wu, L., & He, J. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.09.179 · Cited by 61
The role of fibroblast growth factor 21 in diabetes and its complications: A review from clinical perspective
Liu, J., Foo, J. P., Liu, S., & Lim, S. C. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.02.032 · Cited by 58
Exendin-4 regulates lipid metabolism and fibroblast growth factor 21 in hepatic steatosis
Lee, J., Hong, S., Park, S. E., Rhee, E., Park, C., Oh, K.-W., Park, S. W., & Lee, W. (2014) · Metabolism · doi:10.1016/j.metabol.2014.04.011 · Cited by 52
Incretin‐Based Therapies for the Management of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes
Cusi, K. J. (2019) · Hepatology · doi:10.1002/hep.30670 · Cited by 54
Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates
Александровна, П. В., Bezborodkina, N. N., & Okovityi, S. V. (2022) · Biomedicines · doi:10.3390/biomedicines10020274 · Cited by 55
Gut–Liver–Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies
Marroncini, G., Naldi, L., Martinelli, S., & Amedei, A. (2024) · Biomedicines · doi:10.3390/biomedicines12071398 · Cited by 56
Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease
Liu, Y. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i27.9090 · Cited by 51
GLP‐1 receptor agonists: effects on the progression of non‐alcoholic fatty liver disease
Liu, J., Wang, G., Jia, Y., & Xu, Y. (2015) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2580 · Cited by 48
Exendin-4 Alleviates High Glucose-Induced Rat Mesangial Cell Dysfunction through the AMPK Pathway
Xu, W.-W., Guan, M., Zheng, Z., Gao, F., Zeng, Y., Qin, Y., & Xue, Y. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358623 · Cited by 50
Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review
Pan, C. S., & Stanley, T. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00070 · Cited by 48
Potential of incretin-based therapies for non-alcoholic fatty liver disease
Samson, S. L., & Bajaj, M. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2012.12.005 · Cited by 44
Self-citation
Fibroblast Growth Factor-21 as a Potential Therapeutic Target of Nonalcoholic Fatty Liver Disease
Raptis, D. D., Mantzoros, C., & Polyzos, S. (2023) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s352008 · Cited by 31
Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes
Donate‐Correa, J., Martín‐Núñez, E., Pérez‐Delgado, N., de Fuentes, M. M., Ortíz, A., Fernández, C. M., & Navarro‐González, J. F. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2015.12.003 · Cited by 44
Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Blaslov, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7356 · Cited by 39
Association of GLP-1 secretion with anti-hyperlipidemic effect of ginsenosides in high-fat diet fed rats
Liu, C., Hu, M., Zhang, M., Li, F., Li, J., Zhang, J., Li, Y., Guo, H., Xu, P., Liu, L., et al. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.015 · Cited by 38
MicroRNA‑100‑5p inhibits osteoclastogenesis and bone resorption by regulating fibroblast growth factor 21
Zhou, L., Song, H., Gao, L., Yang, L., Mu, S., & Fu, Q. (2018) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2018.4017 · Cited by 38
Effects of Sitagliptin on Nonalcoholic Fatty Liver Disease in Diet-Induced Obese Rats
Beysel, S., Değertekin, C. K., Yılmaz, G., Çakır, N., Arslan, M., & Törüner, F. B. (2013) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2012.0128 · Cited by 36
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Co-agonist of glucagon and GLP-1 reduces cholesterol and improves insulin sensitivity independent of its effect on appetite and body weight in diet-induced obese C57 mice
PATEL, V. G., Joharapurkar, A. A., Dhanesha, N., Kshirsagar, S. G., Patel, K., Bahekar, R. H., Shah, G. B., & Jain, M. R. (2013) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2013-0189 · Cited by 32
Pathophysiology guided treatment of nonalcoholic steatohepatitis
Nguyen, T. A. T., & Sanyal, A. J. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.07018.x · Cited by 29
PTEN Upregulation May Explain the Development of Insulin Resistance and Type 2 Diabetes with High Dose Statins
Birnbaum, Y., Nanhwan, M. K., Ling, S., Perez-Polo, J. R., Ye, Y., & Bajaj, M. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6546-5 · Cited by 31
Self-citation
Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: Results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide
Savvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapies
Galli, M., Abbate, A., Bonaca, M. P., Crea, F., Forte, M., Frati, G., Gaudino, M. F. L., Gibson, C. M., Gorog, D. A., Mehran, R., et al. (2026) · Nature Reviews Cardiology · doi:10.1038/s41569-026-01249-z · Cited by 41
An overview of glucagon-like peptide-1 receptor agonists for the treatment of metabolic syndrome: A drug repositioning.
Rameshrad, M., Razavi, B. M., Lalau, J., Broe, M. E. D., & Hosseinzadeh, H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.41638.9832 · Cited by 30
Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review
Olaywi, M., Bhatia, T., Anand, S., & Singhal, S. (2013) · Hepatobiliary & pancreatic diseases international · doi:10.1016/s1499-3872(13)60092-2 · Cited by 28
Coagonist of GLP-1 and glucagon decreases liver inflammation and atherosclerosis in dyslipidemic condition
Patel, V., Joharapurkar, A., Kshirsagar, S., Sutariya, B., Patel, M., Pandey, D., Patel, H., Ranvir, R., Kadam, S., Patel, D., et al. (2018) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2018.01.004 · Cited by 27
The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target
Liu, W., Huang, S., Shi, K., Zhao, C., Chen, L.-L., Braddock, M., Chen, Y., Feng, W., & Zheng, M. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.944898 · Cited by 26
Improved FGF21 Sensitivity and Restored FGF21 Signaling Pathway in High-Fat Diet/Streptozotocin-Induced Diabetic Rats After Duodenal-Jejunal Bypass and Sleeve Gastrectomy
Liu, Q., Wang, S., Wei, M., Huang, X., Cheng, Y., Shao, Y., Xia, P., Zhong, M., Liu, S., Zhang, G., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00566 · Cited by 27
Pathophysiological mechanisms involved in non-alcoholic steatohepatitis and novel potential therapeutic targets
la Tijera, F. H. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i10.1297 · Cited by 26
Liraglutide Decreases Liver Fat Content and Serum Fibroblast Growth Factor 21 Levels in Newly Diagnosed Overweight Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Li, X., Wu, X., Jia, Y., Fu, J., Zhang, L., Jiang, T., Liu, J., & Wang, G. (2021) · Journal of Diabetes Research · doi:10.1155/2021/3715026 · Cited by 24
Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus
Hu, Y., Liu, J., Zhang, H., Xu, Y., Hong, T., & Wang, G. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.04.005 · Cited by 22
Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis
Passos, P. R. C., Filho, V. O. C., Noronha, M. M., Hyppólito, E. B., Saldanha, E. F., & Motta, R. V. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16752 · Cited by 25
β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet
Gao, Z., Song, G., Ren, L., Ma, H., Ma, B., & Chen, S. (2020) · European Journal of Histochemistry · doi:10.4081/ejh.2020.3160 · Cited by 21
Treatment with exendin-4 improves the antidiabetic efficacy and reverses hepatic steatosis in glucokinase activator treated db/db mice
Dhanesha, N., Joharapurkar, A. A., Shah, G. B., Kshirsagar, S. G., PATEL, V. G., Patel, K., Bahekar, R. H., & Jain, M. R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.06.015 · Cited by 21
Relationship between FGF21 and drug or nondrug therapy of type 2 diabetes mellitus
Guo, C. Y., Zhao, L., Li, Y., Deng, X., & Yuan, G. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29879 · Cited by 21
Lipid profile changes associated with SGLT-2 inhibitors and GLP-1 agonists in diabetes and metabolic syndrome
Premji, R., Nylen, E. S., Naser, N., Gandhi, S., Burman, K. D., & Sen, S. (2022) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2022.0004 · Cited by 18
Effect of Metformin on Fibroblast Growth Factor-21 Levels in Patients with Newly Diagnosed Type 2 Diabetes
Fan, H. J., Sun, X., Zhang, H., Liu, J., Zhang, P., Xu, Y., Pan, Q., & Wang, G. (2016) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2015.0261 · Cited by 18
Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis
Stine, J. G., Welles, J. E., Keating, S. E., Hussaini, Z., Soriano, C. T., Heinle, J. W., Geyer, N. R., Chinchilli, V. M., Loomba, R. S., & Kimball, S. R. (2023) · Nutrients · doi:10.3390/nu15061481 · Cited by 17
Protein posttranslational modifications in metabolic diseases: basic concepts and targeted therapies
Yang, Y., Wu, J., Zhou, W., Ji, G., & Dang, Y. (2024) · MedComm · doi:10.1002/mco2.752 · Cited by 17
Comparing the effectiveness of long-term use of daily and weekly glucagon-like peptide-1 receptor agonists treatments in patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: a network meta-analysis
Xia, Y., Gao, Z., Yang, C., Duan, K., Ren, L., & Song, G. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170881 · Cited by 16
Successful Glycemic Control Decreases the Elevated Serum FGF21 Level without Affecting Normal Serum GDF15 Levels in a Patient with Mitochondrial Diabetes
Murakami, T., Ueba, Y., Shinoto, Y., Koga, Y., Kaneda, D., Hatoko, T., Kato, T., Yonemitsu, S., Muro, S., & Oki, S. (2016) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.239.89 · Cited by 15
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
Riedinger, C. J., Sakach, J. C., Maples, J. M., Fulton, J., Chippior, J., OʼDonnell, B., O’Malley, D. M., & Chambers, L. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2024.07.008 · Cited by 17
Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
Wang, X., Ma, B., Chen, J., You, H., Sheng, C., Yang, P., & Qu, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6620289 · Cited by 16
Ileal Transposition Surgery Decreases Fat Mass and Improves Glucose Metabolism in Diabetic GK Rats: Possible Involvement of FGF21
Yan, K., Chen, W., Zhu, H., Lin, G., Pan, H., Li, N., Wang, L., Yang, H., Liu, M., & Gong, F. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00191 · Cited by 13
A Novel Interacting Protein SERP1 Regulates the N‐Linked Glycosylation and Function of GLP‐1 Receptor in the Liver
Xiao, Y., Han, J., Wang, Q., Mao, Y., Wei, M., Jia, W., & Wei, L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26207 · Cited by 13
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury
Qian, J., Chen, H., Birnbaum, Y., Nanhwan, M. K., Bajaj, M., & Ye, Y. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6650-9 · Cited by 12
Self-citation
Construction of a Fusion Peptide 5rolGLP-HV and Analysis of its Therapeutic Effect on Type 2 Diabetes Mellitus and Thrombosis in Mice
Ni, Z., Zhang, Y., Wang, H., Wei, Y., Ma, B., Hao, J., Tu, P., Duan, H., Li, X., Jiang, P., et al. (2016) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-016-1979-x · Cited by 12
Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 12
Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Patel, H., Pandey, D., Patel, D. N., Sutariya, B., Patel, M. S., Bahekar, R. H., & Jain, M. R. (2017) · Drug Research · doi:10.1055/s-0043-118808 · Cited by 11
Effects of omega-3 fatty acids and pioglitazone combination on insulin resistance through fibroblast growth factor 21 in type 2 diabetes mellitus
Eissa, L. A., Abdel‐Rahman, N., & Eraky, S. M. (2015) · Egyptian Journal of Basic and Applied Sciences · doi:10.1016/j.ejbas.2015.01.002 · Cited by 11
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes
Samms, R. J., Cheng, C., Fourcaudot, M. J., Heikkinen, S., Khattab, A., Adams, J. M., Cersósimo, E., Triplitt, C. L., PUCKETT, C. L., Tsintzas, K., et al. (2022) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00050.2022 · Cited by 10
Effects of Exenatide and Humalog Mix25 on Fat Distribution, Insulin Sensitivity, and β-Cell Function in Normal BMI Patients with Type 2 Diabetes and Visceral Adiposity
Wang, X., Zhao, X., Gu, Y., Zhu, X., Yin, T., Tang, Z., Yuan, J., Chen, W., Ouyang, R., Yao, L., et al. (2020) · Journal of Diabetes Research · doi:10.1155/2020/9783859 · Cited by 9
Complications of Type 1 Diabetes Mellitus are Associated with Renin Angiotensin System: The Role of Physical Exercise as Therapeutic Tool
Evangelista, F. S. (2014) · Pancreatic Disorders and Therapy · doi:10.4172/2165-7092.1000133 · Cited by 9
Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation
Braun, L. R., Feldpausch, M. N., Czerwonka, N., Torriani, M., Grinspoon, S. K., & Stanley, T. L. (2017) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2017.10.002 · Cited by 9
Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD
Carulli, L., Maurantonio, M., Hebbard, L., Baldelli, E., Loria, P., & George, J. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811319290009 · Cited by 8
Biomarkers of Liver Fibrosis
Suk, K. T., Kim, D. Y., Sohn, K. M., & Kim, D. J. (2013) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800096-0.00002-0 · Cited by 7
Direct actions of GLP-1 analogues on AMP-activated protein kinase activity are distinct from cyclic AMP accumulation
Samson, S. L., & Bajaj, M. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.10.032 · Cited by 7
Self-citation
The mechanisms of GLP-1 receptor agonists in liver diseases: their multifaceted impact on immune response and metabolic regulation
Hu, Z., Tian, D., Yang, Z., Zhang, J., Zhang, L., Xu, Y., & Lu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754721 · Cited by 5
Intestinal perfusion of unacylated ghrelin alleviated metabolically associated fatty liver disease in rats via a central glucagon-like peptide-1 pathway
Lv, P., Li, H., Li, X., Wang, X., Yu, J., & Gong, Y. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00217.2023 · Cited by 4
Fibroblast Growth Factor 21 is a Regulator of Energy Metabolism in the Liver and Adipose Tissue
Matikainen, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407869-7.00039-8 · Cited by 3
Treatment of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Bril, F., Ntim, K., Lomonaco, R., & Cusi, K. J. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch20 · Cited by 3
GLP-1 receptor agonists in metabolic dysfunction–associated steatotic liver disease: mechanistic networks and translational implications: a review
Wang, X., Lu, G., Zhou, Y., & Zhao, G. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02891-7 · Cited by 2
Fibroblast Growth Factor 21 as a Regulator of Energy Metabolism in the Liver and Adipose Tissue
Matikainen, N., & Söderlund, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816093-0.00013-6 · Cited by 2
Future Treatments of NASH
Neuschwander‐Tetri, B. A. (2016) · Current Hepatology Reports · doi:10.1007/s11901-016-0300-3 · Cited by 2
Clinical Trials that Utilize MRS as a Biomarker
Lin, A., Rowland, B., & Griffiths, J. R. (2016) · Encyclopedia of Magnetic Resonance · doi:10.1002/9780470034590.emrstm1496 · Cited by 2
Potencial do treinamento físico aeróbio para a prevenção do diabetes tipo 2 induzido por dieta de cafeteria: papel do tecido adiposo branco.
Higa, T. S. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.39.2012.tde-05022013-081445
Glucagon-like peptide-1 in nonalcoholic steatohepatitis
Armstrong, M. J. (2014) · University of Birmingham Institutional Research Archive (University of Birmingham)
Stéatose et résistance à l’insuline : implication des hépatokines
Bertrand, C., Valet, P., & Castan‐Laurell, I. (2015) · Obésité · doi:10.1007/s11690-015-0492-7
Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-20538-0_16

Authors: Samson, S. L., Sathyanarayana, P., Jogi, M., Gonzalez, E. V., Gutierrez, A., Krishnamurthy, R., Muthupillai, R., Chan, L., & Bajaj, M.
Affiliations: Baylor College of Medicine (US)
Baylor St. Luke's Medical Center (US)
Corresponding author: Bajaj, M.
ORCID: Samson, S. L.
Sathyanarayana, P.
Gutierrez, A.
Krishnamurthy, R.
Muthupillai, R.
Chan, L.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2011-09-29
Volume: 54
Issue: 12
Pages: 3093-3100
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-011-2317-z
PMC: PMC3658171
OpenAlex: W2040507318
Cited by: 110
References: 21
Citations by year: 2026: 5 · 2025: 2 · 2024: 6 · 2023: 4 · 2022: 5 · 2021: 3 · 2020: 9 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 12 · 2015: 15 · 2014: 14 · 2013: 8 · 2012: 8
FWCI: 3.87
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
Locations: Diabetologia (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: American Diabetes Association
American Diabetes Association Research Foundation
Eli Lilly and Company
Amylin Pharmaceuticals
National Institutes of Health
National Heart, Lung, and Blood Institute (T32HL066991, HL-51586, R01HL051586)
National Institute of Diabetes and Digestive and Kidney Diseases (P30DK079638)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords: exenatide, FGF21, FGF21 resistance, non-alcoholic fatty liver disease, type 2 diabetes, pioglitazone, exendin-4, hepatic steatosis, AMPK, acetyl-CoA carboxylase, combination therapy, diet-induced obesity
MeSH terms: Pioglitazone, Exenatide, Adult, Aged, Animals, Body Weight, Diabetes Mellitus, Type 2, Disease Models, Animal, Drug Therapy, Combination, Edema, Fatty Liver, Female, Fibroblast Growth Factors, Humans, Hypoglycemic Agents, Liver, Male, Metformin, Middle Aged, Nausea, Obesity, Peptides, Venoms, Lower Extremity, Thiazolidinediones, Mice, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks